Mode
Text Size
Log in / Sign up
Phase 4 N=150 Randomized Prevention

The Role of Verapamil in Radial Artery Spasm

Radial Artery Spasm

Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Number of Participants With Clinical Radial Artery Spasm (RAS) — 23; 3 participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Verapamil (Drug)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Mersin Medicalpark Hastanesi
Primary completion
Nov 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Clinical Radial Artery Spasm (RAS)
23; 3
PRIMARY
Number of Participants With Ultrasonographically Confirmed Radial Artery Spasm (Ultrasonographic RAS)
36; 8
SECONDARY
Number of Participants With Procedural Success
75; 75
SECONDARY
Mean Volume of Contrast Media Used (mL) (mL)
133.8; 136.4
SECONDARY
Mean of the Dose Area Product (DAP)
873.9; 878.8
SECONDARY
Mean of the Fluoroscopy Time
7.9; 6.9

Summary

Coronary angiography (CAG) is an invasive imaging method performed to determine the degree of coronary artery disease. Radial artery spasm (RAS) is one of the most common complications during coronary angiography performed via the transradial approach, causing patient discomfort or sometimes interrupting the procedure. There are many studies on RAS, and various pharmacoagents administered intravenously (intraarterial) to prevent RAS have been described. However, there is limited data in the literature regarding oral pharmacoagents that will prevent this complication. In our study, the preventive effect of Verapamil, given orally 2 hours before coronary angiography, on radial artery spasm will be investigated.

Eligibility Criteria

Inclusion Criteria

  • Patients who undergo daily coronary angiography
  • Whose Allen test is normal.
  • Must be able to swallow tablets

Exclusion Criteria

  • Allen test results are distorted,
  • No pulse in the radial artery,
  • Patients who have previously undergone radial angiography and whose hemodynamics are compromised will be excluded from the study.
  • Patients with known contraindications to verapamil (significant aortic stenosis, heart rate <50/min, high-grade atrioventricular block, myocardial infarction) complicated with cardiogenic shock, or left ventricular ejection fraction <35%).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06447688). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search